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Effective management of foot and mouth disease (FMD) requires diagnostic tests to
distinguish between infected and vaccinated animals (DIVA). To address this need,
several enzyme-linked immunosorbent assay (ELISA) platforms have been developed,
however, these tests vary in their sensitivity and specificity and are very expensive for
developing countries. Camelid-derived single-domain antibodies fragments so-called
Nanobodies, have demonstrated great efficacy for the development of serological
diagnostics. This study describes the development of a novel Nanobody-based FMD
3ABC competitive ELISA, for the serological detection of antibodies against FMD Non-
Structural Proteins (NSP) in Uganda cattle herds. This in-house ELISA was validated
using more than 600 sera from different Uganda districts, and virus serotype specificities.
The evaluation of the performance of the assay demonstrated high diagnostic sensitivity
and specificity of 94 % (95 % CI: 88.9–97.2), and 97.67 % (95 % CI: 94.15–99.36)
respectively, as well as the capability to detect NSP-specific antibodies against multiple
FMD serotype infections. In comparison with the commercial PrioCHECK FMDV NSP-
FMD test, there was a strong concordance and high correlation and agreement in
the performance of the two tests. This new developed Nanobody based FMD 3ABC
competitive ELISA could clearly benefit routine disease diagnosis, the establishment
of disease-free zones, and the improvement of FMD management and control in
endemically complex environments, such as those found in Africa.
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INTRODUCTION
Foot-and-mouth disease (FMD), is a highly contagious disease
caused by FMD virus (FMDV), which is responsible for
significant economic losses worldwide (1–3). FMDV is classified
within the genus of Aphthovirus a member of the Picornaviridae
family (4, 5). The genome consists of a single-stranded RNA,
∼8 kb in length, which encodes four structural proteins (SPs,
VP1, VP2, VP3, and VP4) and a total of ten mature non-
structural proteins (NSPs; Lpro, 2A, 2B, 2C, 3A, 3B1-3, 3Cpro,
3Dpol (6, 7). The FMDV exists in the form of seven serologically
and genetically distinguishable serotypes named A, O, C, Asia
I, and South African Territories (SAT1, SAT2, and SAT3),
with multiple subtypes within each serotype (8–10). Studies on
outbreaks incidences showed that six of the seven serotypes of
FMDV (O, A, C, SAT1, SAT2, and SAT3) have occurred in Africa
(11, 12), and that currently, the predominant serotypes in Uganda
are serotypes O, SAT1, and SAT2 (12–14).
Global FMD control strategy includes reliable and effective
surveillance and is supported by competent laboratory diagnostic
services (9, 15). Such diagnosis is typically carried out by the
combination of virus isolation, serological tests, and nucleic acid
recognition methods (9, 16). Serological tests are an essential
component in the diagnosis algorithm of FMD because it
is required for animal’s import/export certification, as well
as to determine the “free-from-infection” animal state and
demonstrate vaccine efficacy (17). In this regard, the detection of
antibodies to viral non-structural proteins, NSPs, is considered as
one of the most important indicators of infection, irrespective of
vaccination status (18), and is routinely performed in FMD free
and endemic countries where vaccination is used (19).
Out of the different NSPs studied, the 3ABC polyprotein was
found to be the most reliable single indicator of infection (20).
Currently, most detection assays of antibodies to NSPs are based
on recombinantly expressed 3ABC target antigen (21–26), and
several 3ABC commercial tests (kits) are available today (17, 27).
Although used worldwide, these tests vary in sensitivity and
specificity and are expensive for developing countries (17, 27, 28).
Camilidae such as camels, llamas, and alpacas have a
humoral immune response that has evolved into heavy-chain-
only antibodies (29, 30). Unlike conventional IgGs, the antigen-
binding fragment of these heavy chain antibodies consists of
one single variable domain referred to as VHH or Nanobody
(Nb) (31, 32). Nbs are typically procured by cloning their genetic
repertoire from B cells circulating in the blood of an immunized
animal, constructing a cDNA library and panning by phage
display (31, 32). The Nb is one of the smallest known antigen-
binding antibody fragments. Their reduced size, improved
solubility, high stability, and antigen affinity makes them a
great new generation of detection component for diagnostic
applications (30, 33–35).
This study describes the development and validation of a
new Nb-based FMD 3ABC competitive ELISA for the detection
of anti-FMDV NSP antibodies in cattle serum in Uganda. The
assay demonstrated high sensitivity and specificity to identify
NSP antibodies of several FMD serotype infections with, effective
and robust performance, and potentially low-cost production.
This unique, tailor-made assay could clearly benefit routine
disease diagnosis, the establishment of disease-free zones, and the
improvement of FMD management and control in endemically
complex environments, such as those found in Africa.
MATERIALS AND METHODS
Construction and Expression of FMD 3ABC
Recombinant Protein
FMDV 3ABC gene of serotype O (O1/Israel/99, GenBank:
AF189157.1) containing inactivated 3Cpro protease (26) was
codon optimized for expression in E. coli and synthesized
commercially in the pJ411 expression vector (DNA2.0). In
addition, a six-histidine sequence was added to the 5’ end of the
gene to generate a six-His (6xHis)-tagged protein. The cDNA
construct was transformed into competent E. coli BL21(DE3)
(Stratagene) and plated onto LB agar containing 25µg/ml of
Kanamycin (LB-Kan). A single colony of the transformed E. coli
was inoculated into 10ml of LB-Kan broth and cultured at 37◦C
overnight (ON) with vigorous shaking at 225 rpm. The ON
culture was diluted 1:100 into LB-Kan and grown at 37◦C with
vigorous shaking until the optical density at 600 nm (OD600)
reached 0.6–0.8. Then, the culture was supplemented with 1mM
isopropyl-β-D-thiogalactopyranoside (IPTG) and incubated at
37◦C for an additional 4 h. Following incubation, cells were
harvested by centrifugation at 6000 rpm for 20min and frozen
at−80◦C until further use.
Purification of FMD 3ABC Recombinant
Protein
The E. coli pellet of the cells, containing FMDV 3ABC protein,
was resuspended in a lysis buffer [50mM NaH2PO4, 300mM
NaCl, 5mM β- mercaptoethanol (β-Me) and 10mM imidazole,
pH 8.0], and 1 mg/ml Lysozyme, 3 U/ml Benzonase Nuclease,
and protease inhibitor cocktail (Sigma-Aldrich) at 1:100 dilution
was added to the lysis buffer. After 30min incubation on ice,
the bacterial cell wall was disrupted by ultra-sonication for 1min
at 80 % amplitude (repeated 3 times), on ice. Following the
sonication, broken cells were centrifuged at 10,000 × g for
60min at 4◦C to separate the soluble and insoluble proteins
fraction. FMDV 3ABC recombinant protein was purified from
insoluble fraction and/or inclusion bodies. The insoluble fraction
was washed with lysis buffer containing 1 % Triton X-100
followed by two washes with lysis buffer without Triton X-
100. The insoluble material was dissolved in the denaturing
solubilization buffer (50mM NaH2PO4, [pH 8.0], 300mM
NaCl, 8.0M Urea, and 1mM DTT) and mixed on a platform
shaker for about 1 h at Room Temperature (RT). Then, the
mixture was centrifuged at 10,000 × g for 30min at 4◦C. The
supernatant containing solubilized FMDV 3ABC was collected
and loaded onto Ni-NTA resin (QIAGEN) which was pre-
equilibrated with solubilization buffer. The protein was eluted
from the column with solubilization buffer containing 0.25M
imidazole. Next, FMDV 3ABC protein was refolded by dilution
to a uniform concentration of 0.7 mg/ml and dialyzed against
refolding buffer containing 50mM NaH2PO4, [pH 8.0], 150mM
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NaCl, 8.0M Urea, 3mM reduced Glutathione, 0.3mM oxidized
Glutathione for 4 h at 4◦C. Afterward, another dialysis step
was performed against a buffer containing 50mM NaH2PO4,
[pH 7.5] 150mM NaCl, 3mM reduced Gluthatione, 0.3mM
oxidized Glutathione and 3.0M urea, pH 8.0) at 4◦C ON. The
following day an additional dialysis step was performed for
4 h at 4◦C against the same buffer with Urea concentration of
1.5M. Final dialysis step was performed for 4 h at 4◦C against
a buffer containing 20mM NaH2PO4, 150mM NaCl, and 5 %
v/v glycerol. The dialyzed refolded FMDV 3ABC protein was
then concentrated using a Centricon 30 kDa cutoff, Millipore
(MERCK).
The purity and integrity of FMDV-3ABC protein was assessed
by SDS-PAGE andWestern Blot (WB) as reported elsewhere (26).
For the detection of the 3ABC protein an anti- FMDV-3ABC
camel serum and a commercially anti-6xHis antibody (Sigma)
were used as positive controls while serum from non-inoculated
camel served as negative control.
Ethical Statement
All animal experiments were performed according to Directive
2010/63/EU of the European Parliament for the protection of
animals used for scientific purposes and approved by the Ethical
Committee for Animal Experiments of the Israel (clearance
numbers 11-220-6 and 13-220-3).
Camelus dromedarius Immunization
A healthy camel was immunized with FMDV 3ABC protein
or with four commercially synthesized (Sigma) peptides of
14 to 21 amino acids (aa) long, which represent conserved
sequence motifs derived from FMDV 3ABC protein of all
seven serotypes (36). All peptides were conjugated via their
N terminal Cysteine to keyhole limpet hemocyanin (KLH) or
to Bovine Serum Albumin (BSA; Sigma). The aa sequence
of peptides used during immunization included; peptide 1A,
CISIPSQKSVLYFLIEKGQHEA, derived from FMD 3A protein,
peptide 1B, CGPYEGPVKKPVALKVKAK, derived from FMD
3B protein, and peptides 1C, CRVFEFEIKVKGQDMLSDAAL,
and 2C, CMDGDTMPGLFAYRA, derived from FMDV 3C
protein. During immunization, the camel was injected seven-
times, once every 2 weeks, with FMDV antigen dissolved in PBS
andmixed with an equal volume of Freund’s incomplete adjuvant
(Sigma). The first three injections included 1 mg/injection of the
purified FMDV 3ABC protein. As from the fourth injection, the
camel was injected with a mixture of 0.5mg of FMDV 3ABC
protein and the four different KLH- conjugated peptides, 100
µg/each. After seven injections, peripheral blood lymphocytes
(PBLs) from 100ml of the blood of the immunized camel were
isolated by density gradient using HISTOPAQUE-1077 (Sigma)
and used to construct the Nb library. All camel experiments were
performed according to guidelines approved by the Israel Ethic
Committee.
Generation of Phage-Display Library and
Selection of anti-FMDV-3ABC Nbs
The generation of anti-FMDV 3ABC Nb phage-display library
was performed as previously reported (37). Briefly, PBL were
purified from immunized camel by density centrifugation using
Histopaque-1077 (Sigma-Aldrich). RNA was extracted using
TRIzol reagent (Ambion) according to the manufacturer’s
instruction, and total cDNA was generated using SuperScript
FIRST-Strand Synthesis System (Invitrogen) according to
manufacturer’s instruction. Total cDNA encoding all variable
domains of both, conventional and heavy-chain-only antibodies
was amplified by PCR using the primers CALL001 (5′-
GTCCTGGCTGCTCTTCTACAAGG-3) and CALL002 (5′
GGTACGTGCTGTTGAACTGTTCC-3′). The shortest PCR
amplicon (0.7 kb), comprising the variable domains that
originate from heavy-chain only encoding mRNA, is purified
from a preparative agarose gel and used for a nested PCR using
the primers A6E (5′-GATGTGCAGCTGCAGGAGTCTGGR
GGAGG-3′) and PMCF (5′-CTAGTGCGGCCGCTGAGGA
GACGGTGACCTGGGT-3′). Afterward, PCR products and
pMECS phagemid, were digested with PstI and NotI restriction
enzymes (Roche). The pool of amplified Nb DNA fragments
ligated in the phage-display vector pMECS was transformed
into E. coli TG1 electrocompetent cells to generate a library of
1.0 × 107 transformants. Next, Nbs were phage-displayed as
previously described (37), and bio-panning procedures were
performed against the FMDV 3ABC protein or the mixture of
the four synthetic peptides, which were BSA conjugated for this
step. Positive phage colonies were recovered by alkaline elution
and reamplified for further use in a second and third round
of bio-panning. After three enrichment rounds, ∼100 colonies
were randomly picked, and Nanobodies in the periplasmic
extracts (PE) were screened against FMDV 3ABC protein and/or
peptides for specific binders by ELISA as previously reported
(37) with minor modifications. Briefly, cells containing Nbs were
disrupted by osmotic shock, centrifuged and Nbs residing in
the supernatant were then collected and incubated for 1 h at
RT in microtiter plates (Nunc) precoated with 100 µl/well of
1µg/ml FMDV-3ABC protein or individual synthetic peptides
and incubated. All following assay procedures were performed
as previously described (37). Colonies were considered positive
when the ratio of OD405 nm between the test and control
wells (non-coated well) was ≥ 3. Sequencing of positive-
scoring constructs were then determined by an automated
DNA sequencer (ABI Prism 3100 genetic analyzer; Applied
Biosystems, Foster City, CA, USA), and Nb sequences were
aligned.
Purification of Selected anti-FMD Nbs
Selected anti-FMDV 3ABC Nbs DNA fragments, fused to an
HA tag and 6 x His tag at their C-termini in the pMECS
vector, were transformed into E. coli WK6 and secreted into
the periplasm. After ON bacterial induction at 28◦C with
1mM IPTG, periplasmic extracts containing the soluble anti-
FMDV 3ABC Nbs were obtained by osmotic shock as previously
reported (37). Nbs were then purified using immobilized metal
affinity chromatography (IMAC) on Ni-NTA resin (Sigma-
Aldrich, St. Louis, MO, USA) and gel filtration on Superdex
75 HR 16/60 (Pharmacia, Gaithersburg, MD, USA) in PBS.
The concentration of the Nbs was determined by the OD280nm
measurement and using the individual theoretical extinction
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coefficients as calculated with the EXPASy - ProtParam webtool.
Nbs were then aliquoted and stored at−80◦C until further use.
Sera Samples
A total of 415 serum samples were collected from infected, non-
infected and randomly recovered cattle herds obtained from the
Uganda Virus Research Institute (UVRI), Entebbe, and Makerere
University, Kampala, Uganda (Frank et al., under review). Sera
were collected in Uganda in 2014 and 2015 during FMD
outbreaks and in the following years during 2015 to 2017 from
various cattle herds from previously infected districts as part of a
national surveillance program. In addition, 216 serum samples
collected from naïve and vaccinated calves were also obtained
from the KimronVeterinary Institute (KVI), Beit Dagan, Israel. A
detailed description of all samples that were used during the study
is presented in Table 1. All serum samples used during this work
followed the procedures prescribed and approved by the Uganda
institutional animal ethics committee.
Characterization Affinity of Nbs to FMDV
3ABC Recombinant Protein
Surface Plasmon Resonance Assay
The affinity of selected anti-FMDV 3ABC Nbs was measured
using Surface Plasmon Resonance Assay (SPR) analysis as
previously reported (37). The SPR binding studies were
performed using a Biacore T200 instrument. A CM5 sensor
chip (GE Healthcare) was coupled with 5µg/ml FMDV 3ABC
protein in 10mM sodium acetate pH 5.5, using the amino
coupling chemistry (NHS/EDC; N hydroxysuccinimide N-ethyl-
N’- (dimethylaminopropyl carbodiimide), as recommended by
the manufacturer. The final change in response units (RU) was
840 RU. For affinity measurements, different concentrations
ranging from 500 nM to 1.95 nM of purified Nbs were injected
over the sensor chip at a flow rate of 30 µl/min in HEPES-
buffered saline (HBS; 10mM HEPES, pH 7.5, 150mM NaCl,
3.5mM EDTA and 0.005 % (v/v) Tween 20) running buffer. The
contact time was 120 s followed by a dissociation time of 600 s.
Regeneration was performed for 60 s with 100mM Glycine pH
2.0 followed by a stabilization time of 600 s. Kinetic parameters
were evaluated with the help of the BIA evaluation T200 software
(Biacore) assuming a 1:1 Langmuir binding, with drift.
TABLE 1 | Sera sample bank.
Sample details Sample size Collection Location Collection year




“O” strain 50 2014–2015
“SAT1” strain 50
“SAT2” strain 50
Randomly field collected 165 2016–2017
Total 631
Indirect ELISA
The ELISA procedure was based on a previously described
method (23, 24) with minor modifications. Briefly, Maxisorb
ELISA plates (Nunc) were coated at 4◦C for 16 h (ON) with 100
µl/well of FMDV 3ABC protein at a concentration of 60 ng/ml
suspended in PBS. Following incubation plates were washed three
times with washing buffer [PBS containing 0.05 % Tween 20
(PBS-T)] and then blocked for 1 h at RT with 5 % skimmed
milk (Sigma). The same washing procedure was performed
after each incubation step. Next, serial dilutions of tested Nbs
in concentrations from 4µg/ml to 60 ng/ml were added at a
volume of 100 µl/well and incubated for 1 h at RT. Following
incubation plates were washed and 100 µl/well of 1µg/ml anti-
HA (Sigma) was added and incubated for 1 h at RT. Afterward,
plates were washed and 100 µl/well of 1µg/ml HRP-conjugated
anti-mouse IgG antibody (Sigma) was added and incubated for
an additional 1 h at RT. Finally, plates were washed four times and
90 µl/well of TMB One solution (SouthernBiotech) was added
to develop the color reaction. The color reaction was stopped
after 15min with 1M Sulfuric acid and readouts were obtained
with absorbance read at 470 nm using a standard luminometer
(Thermolabsystems-Luminoskan Ascent).
Nb-Based 3ABC Competitive ELISA
The levels of circulating antibodies to FMDV 3ABC protein were
determined by a novel Nb-based competitive NSP ELISA. In
principle, immunoassay plates (Maxisorp, Nunc) were coated
ON at 4◦C with FMDV 3ABC protein at a concentration of
60 ng/ml in PBS. Following incubation plates were washed three
times in wash buffer (PBS containing 0.1 % Tween-20) and
blocked 1 h at RT with 5 % skimmed milk. The same washing
procedure was performed after each incubation step. After plates
were washed, serum samples diluted 1:25 in diluent buffer (PBS
containing 0.1 % Tween-20 and 1 % skimmed milk) were
dispensed at a volume of 100 µl/well in duplicate and incubated
ON at 4◦C. Following incubation, plates were washed, and 100
µl/well of 0.25µg/ml of the incubated Nb in dilution buffer at
a volume of 100 µl/well was added and incubated for 1 h at RT.
Subsequently, plates were washed, and a commercial monoclonal
anti-HA antibody (Sigma-Aldrich) diluted 1:2000 in dilution
buffer was added into the wells and incubated for 1 h at RT.
Then after washing the plates, 100 µl/well of 1:2000 rabbit anti-
mouse IgG conjugated to HRP was added and incubated for
additional 1 h at RT. Finally, plates were washed four times and
90 µl/well of TMB One solution (SouthernBiotech) was added
to develop the color reaction. The color reaction was stopped
after 15min with 1M Sulfuric acid and readouts were obtained
with absorbance read at 470 nm using a standard luminometer
(Thermolabsystems-Luminoskan Ascent).
Nb Based 3ABC Competitive ELISA Cutoff Value
The cutoff value was determinedwith a control set of 150 negative
cattle sera collected from uninfected animals in Uganda (Frank
et al., under review) and using 10-fold stratified cross-validation
analysis (38). Percent Inhibition (PI) values were calculated for
each serum tested using the formula: 100–(OD tested sample/
OD negative control)× 100. The signal of the negative control is
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obtained by adding no serum only 0.25µg/ml of Nb at a volume
of 100 µl/well. Samples showing a PI value above 51 % were
considered “positive”; and those below 51 %, “negative.”
Nb-Based 3ABC Competitive ELISA Analytical
Sensitivity
The analytical sensitivity of theNb-basedNSP competitive ELISA
was assessed by determining the endpoint dilution of a positive
control serum using a 2-fold dilution series from 1:5 to 1:320. The
endpoint was the dilution at which the value for the positive test
sample was below the cutoff value and could not be discriminated
from that of the negative control.
Nb-Based 3ABC Competitive ELISA Diagnostic
Sensitivity (DSe) and Specificity (DSp)
The Nb-based NSP competitive ELISA was evaluated with
diagnostic performance parameters using sera (n = 466) from
cattle with a known FMDV infection, and non-infected or
unexposed cattle sera (Frank et al., under review). Samples (n =
316) collected from cattle with no previous history of exposure
to FMDV or vaccination, which tested negative in the PrioHECK
FMDV NSP test were used to estimate the relative DSp of the
Nb-based 3ABC competitive ELISA. Of these, 72 were from
naïve and 144 form vaccinated calves collected in Israel. DSe was
calculated using a total of 150 sera samples from post-outbreak
sera from naturally infected animal’s cattle collected in Uganda
and confirmed as having been infected using the PrioCHECK
FMDV NSP test.
Nb-Based 3ABC Competitive ELISA Comparison
With PrioCHECK FMDV NSP Test
PrioCHECK FMDV NSP test (Prionics Lelystad, The
Netherlands) was carried out following manufacturer’s
instructions. After color development was stopped PI values
were calculated. Samples showing a PI value above 50 % were
considered “positive” for FMDV NSP antibodies; and those
below 50 %, “negative.”
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
software 6.01 (GraphPad Software, Inc. LA Jolla, CA, USA).
Differences in values between study groups were assessed by
analysis of variants (ANOVA) and Wilcoxon rank sum test;
p-values represent 2-sided p-values, and p-values <0.05 were
considered statistically significant. For statistical comparison, the
correlation, and agreement analysis between the Nb-based 3ABC
competitive ELISA and PrioCHCK FMDV NSP test was done by
calculating the kappa coefficient, and preforming Bland-Altman
analysis (GraphPad), respectively, for the results obtained in both
tests across all categories of sera.
RESULTS
Construction of FMD 3ABC Recombinant
Protein and Peptides
A recombinant 3ABC protein was used for the detection of
specific FMDV NSP antibodies. The construction and cloning
of the FMDV 3ABC recombinant viral gene (serotype O1,
GenBank: AF189157.1) included an inactivated 3Cpro/mut and
a 6 × His tag marker. In addition, four peptides derived
from FMDV genes 3A, 3B, and 3Cpro were also synthesized
(one from 3A and 3B and two from 3C referred to as 3C1
and 3C2). These specific peptides were selected based on their
amino acid sequence conservation among the seven serotypes
of FMDV and therefore have the potential to interact with
antibodies against NSP of multiple viral serotype strains. WB
analysis was performed for the detection of FMDV3ABCprotein,
using an FMDV-3ABC immunized camel serum, vs. a non-
immunized camel serum as negative control. Since FMDV-
3ABC recombinant was recombinantly expressed as a His-tagged
protein, an anti-His monoclonal antibody was also used as a
second positive control. The results presented in Figure S1 shows
a specific distinct band, corresponding to a molecular weight
of ∼50,000 kd representing FMDV 3ABC recombinant protein.
This distinctive band was only detected when blotted against
immunized camel serum or with an anti-His tag antibody control
(Figure S1A). As expected non-immunized serum showed no
immunoreactivity toward FMDV 3ABC protein. Additional
immunoreactivity specificity was also validated by using the
FMDV 3D recombinant protein as a negative antigen control.
The results of 3ABC immunized camel sera blotted against these
two recombinant viral proteins showed a distinctive band only
against FMDV 3ABC recombinant protein blot (Figure S1B).
Coomassie blue staining result is also presented (Figure S1C).
Selection of anti-FMDV 3ABC Protein
Nanobodies
The Nbs against FMDV 3ABC recombinant protein were
identified and isolated from an immune phage-displayed Nb
library as schematically shown in Figure S2. A total of more
than 100 Nbs were isolated and tested, against FMDV 3ABC
recombinant protein and peptides (3A, 3B, 3C1, and 3C2).
Screening results after panning, partly presented in Figure 1,
reveal five classes of Nbs with distinctive immunorecognition
profile to FMDV protein and peptides. Most of the isolated Nbs
were able to demonstrate positive immunorecognition of either
a single FMDV peptide or the protein. Out of a total of 100
Nbs tested, two Nbs, (i.e., Nb19 and Nb94) showed the capacity
to strongly recognize 3ABC recombinant protein as well as an
additional viral peptide 3C2. These two Nbs, along with four
other Nbs (i.e., Nb1, Nb4, Nb38, and Nb88) that demonstrated
high immunoreactivity solely to FMDV 3ABC recombinant
protein, were selected for further evaluation. Additionally,
Nb9, which showed low immunoreactivity to FMDV 3ABC
recombinant protein or peptides, was also used as a negative
control (Figure 1).
The selected Nbs were then evaluated for their binding affinity
to FMDV 3ABC recombinant protein using SPR analysis and
indirect ELISA. The SPR results presented in Table S1 show that
five out of six Nbs tested had high binding affinity to FMDV
recombinant 3ABC protein, with KD-values ranging from 1.67
to 9.37 10−8 M (Table S1). The indirect ELISA data presented
in Figure 2A yielded similar binding affinity as the SPR analysis,
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FIGURE 1 | Selection of Nanobodies (Nbs) from an immune phage-displayed Nb library against FMDV 3ABC protein. Periplasmic Extract (PE) ELISA results
demonstrating 19 Nb colonies analyzed for the immunorecognition to FMDV 3ABC protein and peptides (3A, 3B, 3C1, and 3C2). Luria-Bertani (LB) broth medium
was used as negative control. Assay cutoff is indicated by dash line.
demonstrating all Nb tested to have high immunoreactivity to
FMDV 3ABC recombinant protein. As expected Nb9 showed
low binding affinity and immunoreactivity capacity in both
methods (Table S1 and Figure 2A). Additional assessment of
Nbs performance was carried out using the preliminary format
of the competitive ELISA. The results presented in Figure 2B
revealed that out of the six Nbs, Nb94 demonstrated the highest
PI of 40 %, compared to∼20 % for the other Nbs tested. Based on
the overall performance, Nb94 was selected for the construction
of the in-house Nb-based 3ABC competitive ELISA.
The Construction of the In-house
Nb-Based FMD 3ABC Competitive ELISA
Using Nb94 as a competitive component, an in-house 3ABC
ELISA for the detection of FMD NSP antibodies in cattle serum
was developed and validated. The development of the assay
included the assessment of various parameters such as the antigen
and Nb94 concentration, sera dilution, incubation times, and
temperature conditions (represented in Figure S3). A schematic
presentation of the assay configuration is shown in Figure S4.
In addition, an evaluation was performed for the analytical
performance of the assay, including diagnostically sensitivity and
specificity, lower limit of detection, and repeatability (Figure 3).
The results presented in Figure 3A show the assay to be
highly predictable with an AUC (Under the Curve) of 0.985 as
determined by Receiver-Operating Characteristic analysis (ROC)
using a total of 222 sera (from infected, non-infected, and naïve
animals). The Nb-based 3ABC competitive ELISA demonstrated
high analytical sensitivity and specificity of 94 % (95 % CI: 88.9–
97.2) and 97.67 % (95 % CI: 94.15–99.36) respectively. Lower
limit of detection calculated using a set of positive (infected sera
sample) and negative (non-infected sera sample) control serum,
and presented in Figure 3B, demonstrated clear discrimination
between seropositive and negative controls using dilutions in
the range of 1:5 to 1:200, with positive control yielding high PI
values (≈ 90 %) down to a 1:50 dilution, after which the PI
values gradually decreased. Inhibition was still seen at a dilution
of 1:200. Overall the assay was highly repeatable, as determined
by the set of the positive and negative controls tested on different
days and by different operators (Figure 3C).
Sera Screening
Infected, Non-infected, Naïve, and Vaccinated
Samples
A total of 250 serum samples collected in 2014-2015 from
infected and non-infected cattle herds in Uganda were delivered
to UVRI. Out of these, 150 and 100 samples were previously
tested using commercially-available PrioCHECK NSP ELISA
(39) and classified as positive or negative for the presence of
antibodies against FMDVNSP, respectively. Out of the 150 serum
samples three groups of 50 each, were obtained from animals
from which FMDV serotype O, serotype SAT1, and serotype
SAT2 were isolated from esopharingeal fluids (probang) samples
(Frank et al., under review; (40)). A comprehensive screening
analysis of these samples was performed by the Nb-based NSP
competitive ELISA. The results presented inTable 2 and Figure 4
showed that 94 % of all infected samples (141 out of 150) were
positive for NSP antibodies, where 98 % were diagnosed positive
for serotype O samples (49 out of 50), 96 % for serotype SAT1
(48 out of 50), and 84 % for serotype SAT2 (42 out of 50).
Screening results of non-infected serum samples demonstrated
high specificity of 96%, with 96 out of the 100 samples tested were
negative for NSP antibodies presence (Table 2 and Figure 4).
In addition, a total of 216 serum samples were obtained from
KVI, Bet Dagan, Israel. These samples were collected from 72
calves at three different time points representing different FMD
vaccination status: naive uninfected and unvaccinated, and those
that received first vaccination and second vaccination. The results
presented in Table 2 and Figure 5A showed the Nb-based 3ABC
competitive ELISA to have 100 % specificity for the naïve group
(72 out of 72 negatives), 99 % for calves after first vaccination
(71 out of 72 negative), and 93 % for calves after two sets of
vaccination (67 out of 72 negative). Comparison of the different
sample groups presented in Figure 6 demonstrated significant
discrimination (P < 0.001) between FMD infected samples to
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FIGURE 2 | Binding affinity analysis of selected Nanobodies (Nbs) against FMDV 3ABC protein. (A) The binding affinity results of six anti-FMDV 3ABC Nbs, evaluated
by indirect ELISA. During experiments Nb9 was used as a negative control. The results are presented in Relative Light Units (RLU). (B). The immunorecognition
performance of six selected anti-FMDV 3ABC Nbs in a competitive ELISA format using a set of 8 infected and noninfected control samples. Mean percentage of
inhibition (PI) for each Nb was calculated using the formula: 100–(X Aver infected/X Aver noninfected) × 100.
FIGURE 3 | Diagnostics performance of the Nanobody (Nb94) based 3ABC competitive ELISA. (A) Receiver-Operating Characteristic (ROC) analysis results from a
total of 222 cattle sera. Dotted lines represent 95 % confidence interval. (B). Lower limit of detection (LLD) using positive (infected sera) and negative (noninfected
sera) control serum. Cutoff assay is indicated by dash line. (C) Intra assay repeatability performance was assessed using a set of positive and negative internal control
sera tested in the assays in different days and by different operators. Lower and upper limits (2×STDV) are indicated by dot lines. Cutoff assay is indicated by dash
line. The total average and STDV of positive and negative internal control sera across the different experiments is also presented. Statistical analysis: *P < 0.05, **P <
0.01, ***P < 0.001.
FMD free, and vaccinated, with mean PI of 70 compared to 20
and 35 %, respectively.
Randomized Cattle Herds in Uganda
The UVRI health workers collected a total of 165 serum samples
from four districts in Uganda during 2016-2017 as part of a sera
surveillance study to assess the levels of FMD NSP antibodies in
cattle herds. These samples were analyzed using the Nb-based
3ABC competitive ELISA. Out of the 165 samples, 80 samples
were collected in Nakasake district, 65 in Mbale district, 13 in
Isingiro district, and 7 in Gomba district (see Table 3). The
results presented in Table 3 and Figure 7 showed that 21 out of
80 samples collected in Nakasake were defined positive for the
presence of FMD NSP antibodies, 9 out of 65 in Mbale, 4 out of
13 in Isingiro, and 0 in Gomba. In total, a prevalence of 20 % of
FMD NSP antibodies (34 out of 165), was found in these groups
of randomly collected samples.
Diagnostic Performance of the Nb-Based
3ABC Competitive ELISA Compared to
Priocheck Nsp Test
The Nb-based 3ABC competitive ELISA results were compared
with a PrioCHECK FMDV NSP test. A total of 631 serum
samples were tested and analyzed in both assays. These samples
represented different FMD state, including naïve, non-infected,
infected, vaccinated, and randomized field samples survey
(Table 1). The results presented in Table 2 and Table 3 showed
a strong correlation between the Nb-based 3ABC competitive
ELISA and PrioCHECK FMDV NSP test. High concordance
between the two assays was observed for the samples collected
from naïve, non-infected, FMD serotype O and SAT1 infected,
and first time vaccinated calves (97–99 %). Samples collected
from animals infected with FMD serotype SAT2 and second
time vaccinated animals showed a lower concordance of 88–90 %
(Table 2). The comparison of the randomized field samples
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TABLE 2 | Performance of Nanobody (Nb94) based 3ABC competitive ELISA in comparison to FMDV PrioCHECK NSP test.
Sample Category Sample size In-house 3ABC competitive ELISA FMDV PrioCHECK NSP test Concordance (%)
Positive (%) Negative (%) Positive (%) Negative (%)
Naïve 72 0/72 (0 %) 72/72 (100 %) 2/72 (3 %) 72/72 (97 %) 97 %
Non-infected 100 4/100 (4 %) 96/100 (96 %) 3/100 (3 %) 97/100 (97 %) 99 %
FMD Infected 150 141/150 (94 %) 9/150 ( 6 %) 148/150 (98 %) 2/150 (2 %) 95 %
“O” strain 50 49/50 (98 %) 1/50 (2 %) 50/50 (100 %) 0/50 (0 %) 99 %
“SAT1” strain 50 48/50 (96 %) 2/50 (4 %) 49/50 (98 %) 1/50 (2 %) 99 %
“SAT2” strain 50 42/50 (84 %) 8/50 (16 %) 49/50 (98 %) 1/50 (2 %) 88 %
Vaccinated 144 6/144 (4 %) 138/144 (96 %) 12/144 (8 %) 132/144 (92 %) 96 %
1st vaccination 72 1/72 (1 %) 71/72 (99 %) 0/72 (0 %) 72/72 (100 %) 99 %
2nd vaccination 72 5/72 (7 %) 67/72 (93 %) 12/72 (17 %) 60/72 (83 %) 90 %
Total 466
FIGURE 4 | Sera screening analysis of infected and noninfected cattle samples using the Nanobody (Nb94) based 3ABC competitive ELISA. Box plot representing
100 noninfected (negative) and 150 infected (confirmed by reverse transcription PCR or virus isolation) (positive) sera collected in Uganda. FMDV serotype of infected
cattle, included serotype O, SAT1 and SAT2 (50 samples for each). Cutoff assay is indicated by dash line. Numbers in brackets indicate the total number of tested sera.
survey exhibited an accordance of 96 % between both assays
(Table 3). Data analysis revealed 7 % (5/72) of animals that
received two vaccinations were diagnosed positive for the
presence of NSP antibodies when tested by the Nb-based
3ABC competitive ELISA, compared to 16.6 % detected in the
PrioCHECK test (12/72) (Figures 5A,B, respectively). Similar
prevalence levels were seen in both assays for samples from
infected and randomly collected animals (98 % to 94 %, and 24
% to 20 %, respectively). Data analysis, estimated by calculating
the kappa coefficient value (GraphPad software), demonstrated
a strong correlation between both assays with a value of 0.875
and SE of 0.021 (95 % CI: 0.834 to 0.916) for all samples across
all categories. Further data analysis using Bland-Altman method
(GraphPad software) presented in Figure S5, also revealed high
agreement between both assays with a Bias value of 0.92, SD of
1.36 and 95 % limits of agreement;−1.74 to 3.58.
DISCUSSION
FMD is an acute and highly contagious disease of cloven-hoofed
animals, which can lead to devastating economic losses across
many parts of the world (9, 41). Over the years, extensive efforts
have been invested to improve the performance of diagnostic
tests for FMD, resulting in the development of a wide range
of ELISA tests to detect the presence of anti-NSP antibodies
(22, 23, 25, 39, 42, 43). Although several 3ABC commercial
tests (kits) are available, these tests are not ideal since they
are extremely expensive and have raised concerns regarding
sensitivity and specificity performance, especially in endemically
complex surroundings (15, 44–46).
To address the environmental needs and to overcome the
challenges of the endemically multiple settings, a novel Nb-
based FMD 3ABC competitive ELISA was developed for the
detection of antibodies against NSP in cattle sera in Uganda.
The design of this in-house assay included the use of a high-
affinity Nb (Nb94), which targets the FMDV 3ABC protein,
and more specifically, a conserved region located within the
FMDV 3Cpro protein. The selection of this Nb with an
immunoreactivity profile to both the complete protein and
a specific conserved region was proven to be highly critical,
enabling the detection of multi-FMD serotype strains in a single
assay configuration. The nature characteristics of Nbs, including
their structural stability, solubility, scalable and straightforward
production, their elevated thermostability, and long shelf-life
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FIGURE 5 | Sera screening analysis of naïve and vaccinated calves’ samples using the Nanobody (Nb94) based 3ABC competitive ELISA and PrioCHECK NSP test. A
total of 72 calves were serially sampled three times; before first vaccination (naïve state), after first vaccination, and after second vaccination. The prevalence of FMDV
NSP antibodies were determined by the Nb (Nb94) based 3ABC competitive ELISA (A) and PrioCHECK NSP test (B). Cutoff for each assay is indicated by dash line.
FIGURE 6 | Comparison analysis of serum samples tested by the Nanobody (Nb94) based 3ABC competitive ELISA. Serum collected from cattle with different FMD
status were analyzed for NSP antibodies presence by the Nb (Nb94) based 3ABC competitive ELISA. These included free (naïve and noninfected), infected (FMDV
serotype O, SAT1 and SAT2) and vaccinated (first and second vaccination). The mean results of percentage of inhibition (PI) is presented. Cutoff assay is indicated by
dash line. Statistical analysis: *P < 0.05, **P < 0.01, ***P < 0.001.
(47) were the key reasons for using them as the competitive
component in the development of the assay. Also, the use of
Nbs provides a significant economic benefit. They potentially
enable development of detection tools, with longer shelf-life
and eliminates the need for temperature-controlled storage
and supply chain, which are extremely important in changing
surrounding such as presented in Africa. Also compared to
mAbs, Nbs distinctive structural properties (devoid of a light
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TABLE 3 | Sera screening analysis, of randomly collected field samples, tested by the Nanobody (Nb94) based 3ABC competitive ELISA and FMDV PrioCHECK NSP test.
Field collected samples Sample size In-house 3ABC competitive ELISA FMDV PrioCHECK NSP test Concordance (%)
Uganda district Positive (%) Negative (%) Positive (%) Negative (%)
Nakasake 80 21/80 (26 %) 59/80 (74 %) 20/80 (25 %) 60/80 (75 %) 99 %
Mable 65 9/65 (14 %) 56/65 (86 %) 15/65 (23 %) 50/65 (77 %) 90 %
Isingiro 13 4/13 ( 30 %) 9/13 (70 %) 5/13 (38 %) 8/13 (62 %) 92 %
Gomba 7 0/7 (0 %) 7/7 (100 %) 0/7 (0 %) 7/7 (100 %) 100 %
Total 165 34/165 (20 %) 131/165 (80 %) 40/165 (24 %) 125/165 (76 %) 96 %
FIGURE 7 | Sera screening of randomly collected field samples tested by the
Nanobody (Nb94) based 3ABC competitive ELISA. A total of 165 cattle
serums previously collected from four different districts (Mbale, Nakasake,
Insingiro, and Gomba) in Uganda, by the Uganda Virus Research Institute
(UVRI), were obtained and analyzed using the Nb (Nb94) based 3ABC
competitive ELISA. Samples were collected as part of an FMD surveillance
program for assessing the levels of NSP antibodies prevalence in the country.
Cutoff assay is indicated by dash line. Numbers in brackets indicate the total
number of sera tested in each district.
chain, and only comprising a single, variable heavy chain
domain) facilitate their construction, which results in lower
production costs. They were shown to be efficiently expressed
in economic production systems, such as bacteria and yeast,
with high batch-to-batch consistency (48), which allow their
production on a large scale and a short period. Considering the
above, the use of Nbs in our competitive ELISA format provides
the assay, if needed, the capacity for easy adjustment for specific
detection of other FMDV serotypes based on 3ABC or any other
proteins selected.
The new Nb-based competitive ELISA was designed for
detection of antibodies against FMD NSP. This was done since
NSP antibodies have been widely accepted as a reliable method
for diagnosing the infection status of animal herds, regardless
of vaccination status (17, 49–52). Furthermore, the presence of
these antibodies provides critical input for the risk analysis in
the assessment of FMD control management (44, 53), and it is
currently the most sensitive tool to distinguish present from past
infection with FMDV after a single time-point sampling (17).
The Nb-based 3ABC competitive ELISA was evaluated
by screening a wide range of serum samples representing
different FMD serotype infection and state. These serum
samples were obtained from cattle herds in Uganda and Israel
considered FMD free (naïve and clinically non-infected), FMD
infected (serotype O, SAT1, and SAT2 infection), and FMD
vaccinated (first or second vaccine admission). The analytical
performance of the assay was assessed using ROC analysis, which
demonstrated the assay high predictive strength, as well as its
high diagnostic sensitivity and specificity. Strong repeatability
and clear discrimination between infected animals, naive/non-
infected, and vaccinated animals was also observed. The
screening results demonstrated the Nb-based 3ABC competitive
ELISA could successfully differentiate between infected and
vaccinated animals (DIVA). This capability was highlighted by
the high numbers of positive samples detected by the assay in the
infected animal group (141 out of 150), compared to the low to
non-positive samples determined in the vaccinated (1 out of 72
after first vaccination, and 5 out of 72 after second vaccination),
and naive (0 out of 72) groups. The assay showed also the capacity
to detect NSP antibodies in sera samples collected from cattle
infected by three different FMD serotypes, with total sensitivity
of 94 % (95 % CI: 88.9–97.2) and specificity of 97.67 % (95 %
CI: 94.15–99.36), as determined by testing a set of naïve and
non-infected samples.
The Nb-based 3ABC competitive ELISA performance was
compared with the commercial PrioCHECKNSP ELISA test that
is widely used in Uganda (17, 49). This comparison demonstrated
high correlation and agreements between assays for all serum
samples regardless of their FMD status. Interestingly, although
both assays showed that calves exhibited an increase in their NSP
antibody response after two shots of vaccines, the PrioCHECK
NSP ELISA test has defined a double number of positive
samples compared to the Nb-based 3ABC ELISA (12 and
5, respectively). Although limited by sample numbers, this
result is consistent with previous reports showing that the
specificity of the PrioCHECK NSP test dropped significantly
after multiple doses of vaccination (17, 43, 54). In theory, the
detection of antibodies against NSPs indicates infection rather
than vaccination, however, in practice, antibodies against NSPs
may also be provoked by trace amounts of NSPs present in
commercial vaccines and multiple vaccinations (18, 20, 50, 55).
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Since under ideal conditions vaccinated animals should not elicit
NSP antibodies, the lower positive NSP antibodies samples seen
by the Nb-based 3ABC competitive ELISA could suggest a higher
specificity of our assay compared to the PrioCHECK NSP test.
To further validate assay performance, a small randomized trial
consisting of serum samples collected from individual cattle
field herds in different districts in Uganda were also analyzed.
The results revealed a total prevalence level of 20 % for NSP
antibodies by the Nb-based 3ABC competitive ELISA. Although
this cohort represents limited sample numbers, the integrity of
the assay performance is supported, by the PrioCHECK NSP test
analysis that demonstrated a similar NSP antibody prevalence
result of 25 %.
Today, most African countries are still poorly equipped
to control FMD due to lack of infrastructure and financial
resources (15, 45). FMD diagnosis in countries such as Uganda is
mainly based on molecular diagnostic tests and serological assays
such as NSP ELISA (39). Although molecular-based diagnostic
tests have shown a higher analytical sensitivity compared to
serological assays, these systems require sophisticated equipment
and highly trained laboratory staff. Such limitations make
them not practical for routine screening and confine their
use to research institutions (45, 56, 57). As a result, the
focal testing of FMD is carried out in regional and national
reference labs and mainly relies on commercial NSP ELISA kits
(39, 56). Considering the unique environmental and economic
challenges, new tailored serological assays with high diagnostics
performance, low production cost, and without the need for
expensive laboratory equipment are clearly still needed for large-
scale application in FMD control and surveillance.
In this study, we successfully developed and validated a
DIVA Nb-based 3ABC competitive ELISA, for detection of NSP
antibodies in cattle serum. Since every assay development has
its own sets of merits and demerits (58), various parameters
that extensively differ between non-endemic and endemic
surroundings, such as those seen in Uganda, were taken
under consideration during assay design. Further studies with
large sample cohorts and across different animal species must
still be carried out to validate the assay performance before
regulatory authorities can adopt it for routine use. However, this
tailor-made highly sensitive and specific NSP ELISA presented
herein clearly demonstrates the potential to be used as an
alternative/supplemental way for simple, low-cost and effective
method for detection of FMD NSP antibodies, and to serve as
a critical component in FMD regional control management and
surveillance.
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